Recent clinical trial results and regulatory updates in cardiovascular and chronic disease treatments show mixed outcomes for new and existing therapies.
Key Points
The FDA has approved Lilly's Mounjaro (tirzepatide) for the reduction of cardiovascular risk in adults diagnosed with type 2 diabetes.
The phase 3 STAREE trial indicates that atorvastatin reduces major cardiovascular events by 30% in adults aged 70 and older, though it did not extend disability-free survival.
Results from the phase 3 LIBREXIA ACS trial demonstrated that the drug milvexian failed to show a reduction in cardiovascular events following acute coronary syndrome.
The eplontersen phase 3 trial showed a significant reduction in transthyretin amyloid deposits but failed to reduce clinical events associated with TTR amyloidosis.
New research suggests that direct oral anticoagulants (DOACs) provide clinical benefits to atrial fibrillation patients with intermediate stroke risk without significantly increasing major bleeding.
A study of adult veterans shows that initiating oseltamivir treatment within six hours of an influenza diagnosis is linked to a decreased risk of hospital admission.
Vitamin B3 supplementation was found to improve nailfold capillary patterns and quality of life in patients suffering from primary Raynaud phenomenon.
In a study of early-stage chronic lymphocytic leukemia, ibrutinib improved event-free survival for specific genetic subgroups but failed to provide an overall survival benefit.